Literature DB >> 27776333

Large scale accelerator production of 225Ac: Effective cross sections for 78-192MeV protons incident on 232Th targets.

J R Griswold1, D G Medvedev2, J W Engle3, R Copping4, J M Fitzsimmons2, V Radchenko3, J C Cooley3, M E Fassbender3, D L Denton4, K E Murphy4, A C Owens4, E R Birnbaum3, K D John3, F M Nortier3, D W Stracener5, L H Heilbronn6, L F Mausner2, S Mirzadeh4.   

Abstract

Actinium-225 and 213Bi have been used successfully in targeted alpha therapy (TAT) in preclinical and clinical research. This paper is a continuation of research activities aiming to expand the availability of 225Ac. The high-energy proton spallation reaction on natural thorium metal targets has been utilized to produce millicurie quantities of 225Ac. The results of sixteen irradiation experiments of thorium metal at beam energies between 78 and 192MeV are summarized in this work. Irradiations have been conducted at Brookhaven National Laboratory (BNL) and Los Alamos National Laboratory (LANL), while target dissolution and processing was carried out at Oak Ridge National Laboratory (ORNL). Excitation functions for actinium and thorium isotopes, as well as for some of the fission products, are presented. The cross sections for production of 225Ac range from 3.6 to 16.7mb in the incident proton energy range of 78-192MeV. Based on these data, production of curie quantities of 225Ac is possible by irradiating a 5.0gcm-2 232Th target for 10 days in either BNL or LANL proton irradiation facilities.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (139)Ce; (140)Ba; (141)Ce; (143)Ce; (144)Ce; (225)Ac; (226)Ac; (227)Ac; (227)Th; (228)Th; (99)Mo; Actinium; Alpha-emitting; Proton irradiation; Radiotherapy; Thorium

Year:  2016        PMID: 27776333     DOI: 10.1016/j.apradiso.2016.09.026

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  16 in total

Review 1.  α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Authors:  Sophie Poty; Lynn C Francesconi; Michael R McDevitt; Michael J Morris; Jason S Lewis
Journal:  J Nucl Med       Date:  2018-03-15       Impact factor: 10.057

Review 2.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

3.  Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma.

Authors:  Leszek Królicki; Frank Bruchertseifer; Jolanta Kunikowska; Henryk Koziara; Bartosz Królicki; Maciej Jakuciński; Dariusz Pawlak; Christos Apostolidis; Saed Mirzadeh; Rafał Rola; Adrian Merlo; Alfred Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-29       Impact factor: 9.236

4.  Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.

Authors:  Narges K Tafreshi; Darpan N Pandya; Christopher J Tichacek; Mikalai M Budzevich; Zhen Wang; Jordan N Reff; Robert W Engelman; David C Boulware; Alberto A Chiappori; Jonathan R Strosberg; Haitao Ji; Thaddeus J Wadas; Ghassan El-Haddad; David L Morse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-26       Impact factor: 9.236

5.  The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates.

Authors:  S Poty; R Membreno; J M Glaser; A Ragupathi; W W Scholz; B M Zeglis; J S Lewis
Journal:  Chem Commun (Camb)       Date:  2018-03-08       Impact factor: 6.222

Review 6.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 7.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

8.  Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.

Authors:  Valery Radchenko; Alfred Morgenstern; Amir R Jalilian; Caterina F Ramogida; Cathy Cutler; Charlotte Duchemin; Cornelia Hoehr; Ferrid Haddad; Frank Bruchertseifer; Haavar Gausemel; Hua Yang; Joao Alberto Osso; Kohshin Washiyama; Kenneth Czerwinski; Kirsten Leufgen; Marek Pruszyński; Olga Valzdorf; Patrick Causey; Paul Schaffer; Randy Perron; Samsonov Maxim; D Scott Wilbur; Thierry Stora; Yawen Li
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 11.082

9.  Simultaneous Separation of Actinium and Radium Isotopes from a Proton Irradiated Thorium Matrix.

Authors:  Tara Mastren; Valery Radchenko; Allison Owens; Roy Copping; Rose Boll; Justin R Griswold; Saed Mirzadeh; Lance E Wyant; Mark Brugh; Jonathan W Engle; Francois M Nortier; Eva R Birnbaum; Kevin D John; Michael E Fassbender
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 10.  Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.

Authors:  Ján Kozempel; Olga Mokhodoeva; Martin Vlk
Journal:  Molecules       Date:  2018-03-05       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.